HONG KONG, Aug. 27, 2025 /PRNewswire/ — On 27 August, Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended 30 June 2025.
In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leveraged its strong capabilities in innovation and globalization to drive steady business development. During the Reporting Period, the Group’s total revenue reached RMB87.28 billion, industrial operation profit amounted to RMB3.15 billion, and profit attributable to owners of the parent reached RMB661.2 million.
The four core subsidiaries – Fosun Pharma, Yuyuan, Fosun Insurance Portugal and Fosun Tourism Group (“FTG”) – achieved a total revenue of RMB63.61 billion in the first half of 2025, accounting for 73% of the Group’s total revenue. Fosun Pharma’s net profit attributable to the owners of the parent reached RMB1.7 billion, up 38.96% year-on-year. Yuyuan’s core businesses stabilized and began to recover, with the jewelry and fashion segment generating RMB12.9 billion in operating revenue during the first half of the year, including RMB7.6 billion in the second quarter, representing a substantial quarter-on-quarter increase. Fosun Insurance Portugal saw steady growth in both domestic and international businesses, achieving a net profit of EUR133 million, representing a year-on-year increase of 27.6%. FTG’s global operational capabilities continued to improve. Its business volume reached a record high of RMB9.53 billion, and adjusted net profit increased by 42.0% year-on-year.
During the Reporting Period, Fosun’s investment in technology innovation reached RMB3.6 billion, with innovative drug business entering a period of rapid growth, fostering multiple achievements attaining ‘China’s first’ and ‘world’s first’ milestones. Among them, FUMAINING (Luvometinib tablets), a Class I new drug independently developed by Fosun Pharma, was approved for marketing in Chinese mainland, filling the treatment gap in the field of rare tumors. In August 2025, the small molecule orally administered DPP-1 inhibitor developed by Fosun Pharma achieved overseas licensing for a potential total of US$645 million.
HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) independently developed by Henlius, has entered global Phase II clinical trials. It is currently undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, Japan, and Australia, demonstrating significantly stronger competitiveness than leading international pharmaceutical companies in terms of drug safety, efficacy, and R&D progress with the potential to become a broad-spectrum anti-cancer drug. HLX22, an innovative anti-HER2 monoclonal antibody, was granted Orphan Drug Designation (ODD) by the European Commission (EC) for the treatment of gastric cancer, marking it as the first anti-HER2-targeted therapy for gastric cancer to receive ODD approval from both the EU and the US.
Leveraging its business presence and profound industry operations in over 40 countries and regions around the world, Fosun’s overseas revenue reached RMB46.67 billion during the Reporting Period, accounting for 53% of the Group’s total revenue. Henlius’ overseas products profits surged over 200%. As the overseas sales volume of commercialized products continues to rise, the company expects significant growth in overseas revenue and profits for the full year of 2025, with strong momentum likely to continue into 2026.
Club Med’s global performance once again reached a record high. Its business volume amounted to RMB9.25 billion, operating profit reached RMB1.27 billion, representing a year-on-year growth of 11.0%. With strong demand continuing for the summer vacation season and the upcoming snow season, bookings are expected to witness sustainable growth in the second half of 2025 and the first half of 2026.
As of the end of the Reporting Period, the total debt to capital ratio stood at 53%, with debt ratio remaining at a healthy level. In May 2025, the international credit rating agency S&P affirmed Fosun’s credit metrics and maintained its rating outlook as ‘Stable’. The Group’s Hong Kong-listed companies in the Health segment saw a strong market capitalization performance in the first half of 2025, driving a revaluation of underlying asset values.
Guo Guangchang, Chairman of Fosun International, said: “In the first half of the year, we remained steadfast in implementing our core business-focused strategy. Our core segments—pharmaceuticals and healthcare, cultural tourism and consumption, financial services and insurance—delivered steady growth. In particular, we achieved several industry-leading breakthroughs in the innovative drugs, which have not only been well received by the market but will also benefit more patients worldwide. Meanwhile, we continued to strengthen our global operating capabilities, allowing more competitive products and services to accelerate their expansion into international markets and to serve a growing number of families. Looking ahead, we will remain focused on our core businesses, step up innovation efforts, and firmly advance our globalization strategy. Building on our long-established core capabilities, we are committed to driving Fosun’s sustainable growth, scaling new heights in our areas of strength, expanding our leadership across more business areas, and creating greater value for our shareholders and society.”
